PlainPharmaWatch

CMS Open Payments · Program Year 2024

Aytu BioPharma, Inc.

Aytu BioPharma, Inc. reported $14,745.49 across General Payments, Research, and Ownership to 873 physicians and teaching hospitals across 873 transactions.

See the rankings → How this is sourced
$14.7K
All-tracks total
873
Transactions
873
Recipients
+$3.8K
General Payments vs PY2023

Aytu BioPharma, Inc. reported $14,745.49 across all CMS Open Payments tracks (General + Research + Ownership) to 873 physicians and teaching hospitals in Program Year 2024 - ranking #1579 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $14,745.49, averaging $16.89 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer aytu-biopharma-inc Aytu BioPharma, Inc.

$14.7K · #1579/1,925 · 0.0% industry · PY2024

  • TOT $14.7K
  • RANK #1579
  • SHARE 0.0%
  • TXN 873
  • RCP 873
  • CAT 1
  • GEN $14.7K
  • ΔGEN +$3.8K
  • TOP1 0.5%
  • PY 2024

Volume peers

Nearest volume peer: Medela AG ($14.7K)

Les Laboratoires Servier$14.8KAytu BioPharma, Inc. (this)$14.7KMedela AG$14.7KCelltrion Healthcare Canada …$14.7KKub Technologies Inc.$14.7K
All-tracks payment totals near Aytu BioPharma, Inc. (CMS Open Payments PY2024)

Aytu BioPharma, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Aytu BioPharma, Inc.'s CMS-reported General Payments increased by $3.8K (+34.5%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: AYTU BIOPHARMA, INC.PY2023: AYTU BIOPHARMA, INC.PY2024: Aytu BioPharma, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$11.0KPY2024$14.7K
PY2023
$10,959.15
PY2024
$14,745.49

What the Data Shows for Aytu BioPharma, Inc.

Averaging $16.89 per transaction and $16.89 per recipient, Aytu BioPharma, Inc.'s Program Year 2024 total comes to $14,745.49 across 873 transactions and 873 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1579 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Food and Beverage" leads the 1-category general-payment breakdown below at $14.7K (100.0% of General Payments, 873 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Aytu BioPharma, Inc. made 1 types of general payments. "Food and Beverage" is the largest category at $14.7K, 100.0% of General Payments.

How Aytu BioPharma, Inc. divides its payments

How the reported total splits across payment categories

1. Food and Beverage$14.7K
Payment Type Amount Transactions
Food and Beverage $14.7K 873

Recipient Concentration in General Payments

The five largest recipient relationships account for $363.65 (2.5%) of $14,745.49 in this company's General Payments records across 718 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Aytu BioPharma, Inc.

The five named recipients with the highest reported General Payments from this company

Jennifer Caicedo$79.84Hannah Mules$70.96Cathy Gvozden$70.95Andre Gvozden$70.95Eliza Huebner$70.95
  1. 1

    Jennifer Caicedo

    $79.84 across 4 reported transactions

  2. 2

    Hannah Mules

    $70.96 across 4 reported transactions

  3. 3

    Cathy Gvozden

    $70.95 across 4 reported transactions

  4. 4

    Andre Gvozden

    $70.95 across 4 reported transactions

  5. 5

    Eliza Huebner

    $70.95 across 4 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Aytu BioPharma, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Aytu BioPharma, Inc..

Kestra Medical Technology Services, Inc.

HHI 17

Lilly USA, LLC

HHI 16

RedHill Biopharma Inc.

HHI 18

Intuitive Surgical, Inc.

HHI 18

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Aytu BioPharma, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Aytu BioPharma, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.